CoreCap Advisors’s Heron Therapeutics HRTX Stock Holding History

CoreCap Advisors’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$12.1K	Hold	28,409	–	–	﹤0.01%	1998
2026 Q1	$22.7K	Hold	28,409	–	–	﹤0.01%	1617
2025 Q4	$36.9K	Hold	28,409	–	–	﹤0.01%	1448
2025 Q3	$35.8K	Sell	28,409 -54	-0.2%	-$86	﹤0.01%	1443
2025 Q2	$58.9K	Sell	28,463 -123	-0.4%	-$251	﹤0.01%	1182
2025 Q1	$62.9K	Buy	28,586 +28,409	+16,050%	+$55.1K	﹤0.01%	1076
2024 Q4	$271	Buy	+177	New	+$287	﹤0.01%	2659
2022 Q4	$293	Buy	+117	New	+$377	﹤0.01%	2236
2022 Q3	–	Sell	-117	Closed	–	–	1197
2022 Q2	$0	Buy	+117	New	+$470	﹤0.01%	2196
2022 Q1	–	Sell	-117	Closed	-$1K	–	1207
2021 Q4	$1K	Buy	+117	New	+$1.2K	﹤0.01%	2139

Other funds holding HRTX

CPC

Congress Park Capital Saratoga Springs, New York $370M AUM 26.01% 1-Year Est. Return

CWP

Curated Wealth Partners El Segundo, California $774M AUM 5.71% 1-Year Est. Return

Apeiron RIA Dallas, Texas $390M AUM 22.97% 1-Year Est. Return

DIM

DLK Investment Management Solana Beach, California $235M AUM 12.41% 1-Year Est. Return

PFS

Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

Diversified Trust Memphis, Tennessee $6.24B AUM 28.78% 1-Year Est. Return

TWM

TopTier Wealth Management Muskego, Wisconsin $166M AUM

BRWA

B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return

VWM

Venturi Wealth Management Austin, Texas $2.58B AUM 41.25% 1-Year Est. Return

CoreCap Advisors's HRTX Position: Q2 2026 in Review

CoreCap Advisors held its Heron Therapeutics (HRTX) position steady in Q2 2026 at 28,409 shares worth $12.1K. The position accounts for ﹤0.01% of the portfolio, ranked #1998.

CoreCap Advisors first reported a position in HRTX in Q4 2021 and has held it in 10 quarters since. The position peaked at $62.9K in Q1 2025. 13 funds tracked by Wall St. Rank hold HRTX as of Q2 2026.

CoreCap Advisors held 28,409 shares of Heron Therapeutics worth $12.1K as of Q2 2026.
CoreCap Advisors left its Heron Therapeutics share count unchanged in Q2 2026.
Heron Therapeutics made up ﹤0.01% of CoreCap Advisors's portfolio in Q2 2026, its #1998 holding.
CoreCap Advisors first reported a position in Heron Therapeutics in Q4 2021 and has held it in 10 quarters since.
CoreCap Advisors's Heron Therapeutics position peaked at $62.9K in Q1 2025.
13 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2026.

Based on CoreCap Advisors's 13F filing for Q2 2026, filed 6 Jul 2026.